Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 82

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 82
---
-Allotment Option Units, we consummated the
private sale of an additional 30,000 Private Placement Units, generating gross proceeds of $300,000.

12

As of February 18, 2025, a total
of $ 231,150,000 of the net proceeds from the sale of Units in the IPO (including the Over-Allotment Option Units) and the private placement
of the Private Placement Units, were placed in a trust account established for the benefit of the Company’s public shareholders.
The funds in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in
money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government
treasury obligations and/or held as cash or cash items (including in demand deposit accounts).

For a description of the use
of the proceeds generated in our IPO and the private placement of the Private Placement Units, see Part II, Item 7 (Management’s
Discussion and Analysis of Financial Condition and Results of Operations) of this Annual Report on Form 10-K. There has been no material
change in the planned use of proceeds from the IPO and the private placement of the Private Placement Units as described in the Registration
Statement. The specific investments in our trust account may change from time to time.

Purchases of Equity Securities by the Issuer
and Affiliated Purchasers

None.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 

The following discussion and analysis of the Company’s
financial condition and results of operations should be read in conjunction with our audited financial statements and the notes related
thereto which are included in “Item 8. Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. Certain
information contained in the discussion and analysis set forth below includes forward-looking statements. Our actual results may differ
materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth under “Cautionary
Note Regarding Forward-Looking Statements,” “Item 1A. Risk Factors” and elsewhere in this Annual Report on Form 10-K.

Overview

We are a blank check company incorporated
as an exempted company in the Cayman Islands on May 23, 2024 for the purpose of effecting a merger